U.S. patent number 3,874,381 [Application Number 05/473,373] was granted by the patent office on 1975-04-01 for dual nozzle intranasal delivery device.
This patent grant is currently assigned to SmithKline Corporation. Invention is credited to Ronald Baum.
United States Patent |
3,874,381 |
Baum |
April 1, 1975 |
DUAL NOZZLE INTRANASAL DELIVERY DEVICE
Abstract
A dual nozzle intranasal delivery device has a housing with a
cavity for the reception of a container having a pierceable stopper
and having a first passage communicating with said cavity. A hollow
needle secured in the passage extends into the cavity and is
adapted to penetrate the stopper of the container. A pair of
substantially parallel spray nozzles communicate with a second
passage in the housing. A turret member is rotatably mounted in the
housing and has a passage adapted to communicate alternatively with
the first and second passages and having an opening for the
reception of a syringe nozzle. Through the use of the turret a
syringe can be placed in communication with the container and then,
by rotating the turret, placed in communication with the second
passage to provide for taking liquid from the container and
delivering it through the nozzles.
Inventors: |
Baum; Ronald (Merion Station,
PA) |
Assignee: |
SmithKline Corporation
(Philadelphia, PA)
|
Family
ID: |
23879264 |
Appl.
No.: |
05/473,373 |
Filed: |
May 28, 1974 |
Current U.S.
Class: |
128/200.14;
128/203.21; 141/27; 141/383; 604/94.01; 128/203.22; 141/329;
604/229 |
Current CPC
Class: |
A61M
3/00 (20130101); A61M 15/0028 (20130101); A61M
15/0036 (20140204); A61M 15/08 (20130101); A61M
2202/0468 (20130101); A61M 2205/073 (20130101); A61M
15/0091 (20130101) |
Current International
Class: |
A61M
15/08 (20060101); A61M 3/00 (20060101); A61M
15/00 (20060101); A61m 003/00 () |
Field of
Search: |
;128/206,207,208,215,218R,235,247,272,173H ;141/383,329,27,2 |
References Cited
[Referenced By]
U.S. Patent Documents
Primary Examiner: Gaudet; Richard A.
Assistant Examiner: Recla; Henry J.
Attorney, Agent or Firm: Smith, Harding, Earley &
Follmer
Claims
I claim:
1. A dual nozzle intranasal delivery device comprising:
a housing,
said housing having a cavity for the reception of a container
having a pierceable stopper and a first passage communicating with
said cavity,
a hollow needle secured in said passage and extending into the
cavity, said needle being adapted to penetrate the stopper of said
container,
a pair of adjacent nozzles having substantially parallel axes a
second passage in said housing communicating with said nozzles,
a cylindrical opening in said housing,
each of said passages communicating with said opening.
a turret member mounted in said cylindrical opening and having a
passage of which one end alternatively communicates with the first
and second passages and the other end is provided with an opening
for the reception of a syringe nozzle whereby a syringe can be
placed in communication with the container and then by rotation of
the turret placed in communication with the second passage.
2. A device in accordance with claim 1 having stop means to limit
the rotation of the turret to facilitate the alignment of the
passage in the turret with the first and second passages.
Description
BACKGROUND OF THE INVENTION
It is known to employ a pair of adjacent spray nozzles
communicating with a conduit which is adapted to be connected to a
syringe to deliver vaccine such as a flu vaccine or a measles
vaccine in about equal doses to each nostril. While this operation
is simple and effective, it still leaves the patient with a
difficult problem in getting the dosage in liquid form into the
syringe. This is particularly the case where the biological to be
employed is lyophilized. In accordance with this invention a
lyophilized medicament can be placed in solution in a syringe under
sterile conditions with great ease by an unskilled patient.
BRIEF SUMMARY OF THE INVENTION
A dual nozzle intranasal delivery device has a housing with a
cavity for the reception of a container having a pierceable stopper
and having a first passage communicating with said cavity. A hollow
needle secured in the passage extends into the cavity and is
adapted to penetrate the stopper of the container. A pair of
substantially parallel spray nozzles communicate with a second
passage in the housing. A turret member is rotatably mounted in the
housing and has a passage adapted to communicate alternatively with
the first and second passages and having an opening for the
reception of a syringe nozzle. Through the use of the turret a
syringe can be placed in communication with the container and then,
by rotating the turret, placed in communication with the second
passage to provide for taking liquid from the container and
delivering it through the nozzles.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an elevational view of an intranasal delivery device in
accordance with the invention together with a container and a
syringe;
FIG. 2 is a vertical section through the intranasal device of FIG.
1 showing a container and a syringe positioned to communicate with
the container;
FIG. 3 is a vertical section through the intranasal device of FIG.
1 partially broken away and showing a syringe positioned to
discharge liquid through the nozzles;
FIG. 4 is an elevational view of the intranasal device of FIG. 1
with a syringe positioned for the discharge of liquid through the
nozzles; and
FIG. 5 is a view taken on the plane indicated by the line 5--5 in
FIG. 1 and showing a syringe positioned for the discharge of liquid
through the nozzles.
DETAILED DESCRIPTION
An intranasal delivery device 2 has a body 4 formed from two mirror
image portions 6 and 8 which are secured together by screws
indicated at 10. The body 4 has a cavity 12 which is adapted to
receive a container 14 having a pierceable stopper 16 of rubber or
the like. Stopper 16 is held in position by a metal cap 18.
Container 14 is well known in the art.
A passage 22 is in communication with cavity 12. Secured by a
pressed fit in cavity 22 is a hollow needle 24, which has a sharp
chamfered end 25, extends into cavity 12 and is adapted to pierce
the pierceable stopper 16 as shown in FIG. 2.
A cylindrical turret member 26 is rotatably mounted in a partial
cylindrical opening 28 in body 4 which extends for somewhat more
than 180.degree. in order to lock in the turret member 26. Turret
member 26 has a passage 30 which has an enlarged portion 32 and
which is adapted to communicate with passage 22 and is connected to
a tapered opening 34 which is adapted to receive a tapered nozzle
36 of a syringe 38.
Turret member 26 can be rotated clockwise as viewed in FIG. 2 to
place it in communication with a passage 42 in body 4. Passage 42
communicates with a pair of substantially parallel nozzles 44 and
46 which have respectively reduced discharge passages 48 and 50.
Nozzles 44 and 46 are spaced so as to permit the nozzles to be
simultaneously introduced into the patient's nostrils.
A sector stop member 60 is secured to the exterior of turret member
26, for example by an adhesive, and engages body 4 to limit the
rotation of turret 26 so as to communicate with passage 24 in one
position and with passage 42 in its alternate position of maximum
rotation.
Syringe 38 has a rubber stopper 64 to close off nozzle 36 and a
plunger 66 to cause liquid to flow in and out of syringe 38.
OPERATION
Assuming that a lyophilized biological such as a lyophilized
medicament tablet 70 is in container 14, container 14 is inserted
into cavity 12 and thrust home causing needle 24 to pierce
pierceable stopper 16 as shown in FIG. 2. A syringe 38 containing a
reconstituting liquid will have its cover 64 removed with nozzle 36
pointing up and nozzle 36 inserted into opening 34. With passage 30
lined up with passage 22, plunger 66 is advanced to cause liquid to
move out of syringe 38 through passage 30, passage 22 and needle 24
into container 14. When the tablet 70 has gone into solution, the
plunger 66 is retracted to withdraw the solution from container 14
into syringe 38. The syringe 38 then is moved to cause the turret
member 26 to rotate so that passage 30 is in communication with
passage 42. Nozzles 44 and 46 are placed by the user in his
nostrils. Again, plunger 66 is advanced to cause the discharge of
fluid from syringe 38 into passage 42 and thence into the patient's
nose through nozzles 44 and 46.
It will be understood that the foregoing description is
illustrative and is not limiting.
* * * * *